Pleiotropic Effects of PCSK-9 Inhibitors.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors are a group of drugs whose main mechanism of action is binding to the PCSK-9 molecule, which reduces the degradation of the low-density lipoprotein receptor (LDL-R) and, hence, increases the uptake of low-density lipoprotein cholesterol (LDLc) from the bloodstream as well as reducing its concentration. The effectiveness of three monoclonal antibodies, namely, alirocumab (human IgG1/κ monoclonal antibody, genetically engineered in Chinese hamster ovary cells), evolocumab (the first fully human monoclonal antibody), and bococizumab (humanized mouse antibody), in inhibiting the action of PCSK-9 and reducing LDLc levels has been confirmed. The first two, after clinical trials, were approved by the Food and Drug Administration (FDA) and are used primarily in the treatment of autosomal familial hypercholesterolemia and in cases of statin intolerance. They are currently used both as monotherapy and in combination with statins and ezetimibe to intensify therapy and achieve therapeutic goals following the American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines. However, the lipid-lowering effect is not the only effect of action described by researchers that PCSK-9 inhibitors have. This paper is a review of the literature describing the pleiotropic effects of PCSK-9 inhibitors, which belong to a group of drugs that are being increasingly used, especially when standard lipid-lowering therapy fails. The article focuses on activities other than lipid-lowering, such as the anti-atherosclerotic effect and stabilization of atherosclerotic plaque, the anti-aggregation effect, the anticoagulant effect, the antineoplastic effect, and the ability to influence the course of bacterial infections. In this publication, we try to systematically review the current scientific data, both from our own scientific work and knowledge from international publications.

• Authors: Marcin Basiak, Michał Kosowski, Marcin Cyrnek, Łukasz Bułdak, Mateusz Maligłówka, Grzegorz Machnik, Bogusław Okopień
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 22 Issue 6 (Mar 19 2021) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 33808697 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Anticholesteremic Agents
• Anticoagulants
• Antineoplastic Agents
• PCSK9 Inhibitors
• Protease Inhibitors
• PCSK9 protein, human

Topics

• Animals
• Anti-Bacterial Agents (pharmacology)
• Anticholesteremic Agents (pharmacology, therapeutic use)
• Anticoagulants (pharmacology, therapeutic use)
• Antineoplastic Agents (pharmacology, therapeutic use)
• Blood Coagulation (drug effects)
• Humans
• PCSK9 Inhibitors
• Plaque, Atherosclerotic (drug therapy)
• Protease Inhibitors (pharmacology, therapeutic use)
• Protein Aggregation, Pathological (drug therapy)